Beyond the Permissibility of HESC Research: Substantive and Procedural Requirements

California's Stem Cell Initiative: Confronting the Legal and Policy Challenges

Berkeley, March 4th 2006

Rosario M. Isasi, JD, MPH
Centre de recherche en droit public, Université de Montréal
rosario.isasi@umontreal.ca

Countries Surveyed



- 1. Australia
- 2. Austria
- 3. Argentina
- 4. Belgium
- 5. Bulgaria
- 6. Brazil
- 7. Canada
- 8. China
- 9. Colombia
- 10. Costa Rica
- 11. Denmark
- 12. Estonia
- 13. Finland
- 14. France
- 15. Georgia
- 16. Germany
- 17. Greece

- 18. Hungary
- 19. Iceland
- 20. India
- 21. Ireland
- 22. Israel
- 23. Italy
- 24. Japan
- 25. Latvia
- 26. Lithuania
- 27. Netherlands
- 28. New Zealand
- 29. Norway
- 30. Panama
- 31. Peru
- 32. Poland
- 33. Portugal
- 34. Romania

- 35. Russia
- 36. Singapore
- 37. Slovakia
- 38. Slovenia
- 39. Spain
- 40. South Africa
- 41. South Korea
- 42. Sweden
- 43. Switzerland
- 44. Tunisia
- 45. Thailand
- 46. Turkey
- 47. Ukraine
- 48. United Kingdom
- 49. United States
- 50. Vietnam

Survey of National Policies on Embryonic Stem Cell Research

- 32 countries prohibit human cloning for therapeutic or research purposes by law, 05 by guidelines.
- 6 countries allow for the creation of embryos for research purposes by law, 01 country by guidelines.
- 15 countries allow the procurement of hESC from surplus embryos by law, 04 by guidelines.
- 05 countries prohibit the procurement of hESC by law, but 1 country allow for their importation.
- 33 countries have signed (19 have ratified) the European Convention on Human Rights and Biomedicine, which prohibits the creation of embryos for research purposes.

Substantive Requirements (I)

- 1. Constrain research to practices that serve important and worthwhile goals, such as medical therapy (e.g. diagnostic and preventive purposes)
- 2. Prohibit research with non-therapeutic or "trivial" goals (e.g. enhancement, eugenic purposes)

Substantive Requirements (II)

- 3. Identify the circumstances under which heSC and cloning research is ethically justified and establish:
 - A hierarchy and/or an order of priority among embryos used for research (surplus vs. SCNT; embryos low quality vs. not suitable to be placed in the body)
- 4. Prohibit developing, implanting or conducting research on embryos beyond 14 days (from fertilisation) or until formation of primitive streak.

Procedural & Ethical Safeguards (I)

1. Stages of embryonic development:

- Alternative sources.
- Traceability of stem cell lines with respect to their source.
- Prohibition on the creation of animal/human chimeras.

Procedural & Ethical Safeguards (II)

- 2. Donors (e.g. blastocysts, gametes, somatic cells):
 - Free and informed consent.
 - Prohibition of financial incentives.
 - Safeguards against conflicts of interest.
 - Protection of confidentiality and privacy.

Procedural & Ethical Safeguards (III)

3. Research Governance:

- Ethics review
- Government oversight
- Enforcement mechanisms
- Transparency regarding research results





